We use cookies for a better user experience. Read our Privacy Policy

I Agree

Thyroid Gland Disorders Treatment Market

Thyroid Gland Disorders Treatment Market (Disorders - Hypothyroidism (Levothyroxine and Liothyronine) and Hyperthyroidism (Imidazole and Propacil)) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 - 2025

Global Thyroid Gland Disorders Treatment Market: Snapshot

Hormones released by thyroid gland play a crucial role in stimulating metabolism, growth, and calories processing. Globally, thyroid gland disorders such as hypothyroidism, hyperthyroidism, and thyroid nodules affect around 5% to 10% of the population. Hyperthyroidism and hypothyroidism affect majority of the population primarily due to growing incidence of autoimmune diseases such as Grave’s disease and Hashimoto's thyroiditis. Moreover, iodine deficiency is a widespread problem across the globe and is measured as a prime risk factor for the increase in prevalence of thyroid disorders.

The global thyroid gland disorders treatment market is likely to expand at a steady pace due to the rising prevalence of both hyperthyroidism and hypothyroidism across the world. Hyperthyroidism and hypothyroidism are more common in women than in men. Furthermore, factors such as sedentary lifestyle, consistent expanding pool of geriatric population, and initiatives by the key players in thyroid gland disorders treatment market to introduce innovative therapeutic option are key factors influencing the growth of thyroid gland disorders treatment market.

According to the report, the global thyroid gland disorders treatment market accounted for US$ 1,954.7 Mn in 2016 and is anticipated to reach US$ 2,609.9 Mn by 2025 at a CAGR of 3.3% from 2017 to 2025.

global thyroid gland disorders treatment market

Levothyroxine to Continue to Witness High Demand for Treatment of Hypothyroidism

On the basis of disorder, the thyroid gland disorders treatment market has been primarily categorized into two segments: hypothyroidism and hyperthyroidism. The hypothyroidism segment includes drugs such as Levothyroxine and Liothyronine. The hyperthyroidism segment covers drugs such as Propacil and Imidazole.

The thyroid gland disorders treatment market is expanding at a moderate growth rate primarily due to rise in thyroid disorder patient population globally, rise in demand for drugs for hypothyroidism such as Euthyrox and Synthroid in developing and developed regions, and continuous efforts by leading thyroid drug manufacturers to develop advance therapeutics. However, the increased availability of several generic drugs has led to a decline in the overall market revenue.

North America to Remain Lucrative Regional Market, Thanks to High Patient Pool

Based on geographic distribution, North America is the largest market for thyroid gland disorders treatment. According to numbers published by the U.S. Department of Health and Human Services, around 1.2% people in the U.S. suffer from hypothyroidism each year. Moreover, women are 2-10 times more susceptible than men to develop thyroid conditions. High prevalence of thyroid gland disorders, better availability of diagnosis and treatment methods, better awareness among general public, and favorable reimbursements together define the dominance of North America market.

On the other hand, the Asia Pacific market is likely to register the fastest market growth in terms of sales of thyroid gland disorders drugs during the given forecast period. Countries such as India, China, and Japan together determine the market trends in Asia pacific. Large consumption of generic formulations across these countries contribute to the growth of the market, mitigating the lower sales revenue in the region. Recent growth in investments and awareness initiatives by the market incumbents also contribute to the market growth in the Asia Pacific region.

Some of the leading players in the global thyroid gland disorders market are Merck KGaA, Pfizer, Inc., ALLERGAN, Takeda Pharmaceutical Company Limited, Sanofi S.A., AbbVie Inc.,   Lannett Company, Inc., Mylan N.V., Aspen, and Novartis AG. The vendor landscape of the global thyroid gland disorders treatment market is consolidated, with relatively small number of companies accounting for a majority share of the market.

Thyroid Glad Disorders Market - Snapshot

The thyroid gland is a small organ that’s located in the front of the neck, wrapped around the windpipe (trachea). It’s shaped like a butterfly, smaller in the middle with two wide wings that extend around the side of your throat. The thyroid is a gland. You have glands throughout your body, where they create and release substances that help your body do a specific thing.

Thyroid gland disorder is a general term for a medical condition that keeps the thyroid from making the right amount of hormones. Typically, thyroid makes hormones that keep the body functioning normally. When the thyroid gland makes too much thyroid hormone, the body uses energy too quickly. This is called hyperthyroidism. Using energy too quickly will do more than make a person tired — it can make the heart beat faster, cause a person to lose weight without trying and even make you feel nervous. On the flip-side of this, the thyroid can make too little thyroid hormone. This is called hypothyroidism. When a person has this type of thyroid gland disorder, they have too little thyroid hormone in their body, it can make them feel tired or they might gain weight and may even be unable to tolerate cold temperatures. Thus thyroid makes hormones that help control many vital functions of the body.

Standard treatment for thyroid gland disorders involves daily use of the synthetic thyroid hormone levothyroxine (Levo-T, Synthroid, others) depending upon the body requirment. This oral medication restores adequate hormone levels, reversing the signs and symptoms of hypothyroidism. The medication gradually lowers cholesterol levels elevated by the disease and may reverse any weight gain. Treatment with levothyroxine will likely be lifelong, but because the dosage a person might need may change, your doctor is likely to check the TSH level every year.

The global thyroid gland disorders treatment market is segmented as given below:

Disorders

  • Hypothyroidism
    • Levothyroxine
    • Liothyronine
  • Hyperthyroidism
    • Imidazole
    • Propacil

Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

1. Preface 
     1.1. Report Scope and Market Segmentation 
     1.2. Research Highlights

2. Assumptions and Research Methodology 
     2.1. Assumptions and Acronyms Used
     2.2. Research Methodology

3. Executive Summary
     3.1. Global Thyroid Gland Disorders Treatment Market Size (US$ Mn) and Distribution, by Region, 2017 and 2025 
     3.2. Global Thyroid Gland Disorders Treatment Market: Market Snapshot

4. Market Overview
     4.1. Global Thyroid Gland Disorders Treatment Market: Product Overview 
     4.2. Global Thyroid Gland Disorders Treatment Market: Key Industry Developments

5. Market Dynamics
     5.1. Drivers and Restraints Snapshot Analysis
     5.2. Drivers
            5.2.1. Increasing incidence of thyroid gland disorders
            5.2.2. Rise in the number of obese, diabetic, and cardiovascular patients, leading to increased risk of thyroid disorders
            5.2.3. Growing number of disease awareness programs in developing regions 
            5.2.4. Focus on spreading awareness about disorders as well as promotional campaigns
            5.2.5. Development of effective combination thyroid disorders drug therapies
     5.3. Restraints
            5.3.1. Rising customer preference for alternative treatments 
            5.3.2. Asymptomatic nature of thyroid disorders leading to large pool of undiagnosed patients
     5.4.  Opportunities
            5.4.1. Asymptomatic nature of thyroid disorders leading to large pool of undiagnosed patients
            5.4.2. Increase in research and development activities
     5.5. Global Thyroid Gland Disorders (Hypothyroidism and Hyperthyroidism) Epidemiology
     5.6. Global Thyroid Gland Disorders Treatment Market Revenue Forecast
     5.7. Global Thyroid Gland Disorders Treatment Market Outlook

6. Global Thyroid Gland Disorders Treatment Market Analysis, by Disorders
     6.1. Introduction
     6.2. Key Insights
     6.3. Global Thyroid Gland Disorders Treatment Market Analysis, by Disorders
            6.3.1. Hypothyroidism
                     6.3.1.1. Levothyroxine
                     6.3.1.2. Liothyronine
            6.3.2. Hyperthyroidism
                     6.3.2.1. Imidazole
                     6.3.2.2. Propacil
     6.4. Global Thyroid Gland Disorders Treatment Market Forecast, by Disorders
            6.4.1. Hypothyroidism
                     6.4.1.1. Levothyroxine
                     6.4.1.2. Liothyronine
            6.4.2. Hyperthyroidism
                     6.4.2.1. Imidazole
                     6.4.2.2. Propacil
     6.5. Global Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
            6.5.1. Hypothyroidism
            6.5.2. Hyperthyroidism

7. Global Thyroid Gland Disorders Treatment Market Analysis, by Region
     7.1. Global Thyroid Gland Disorders Treatment Market Forecast, by Region, 2015–2025 
            7.1.1. North America
            7.1.2. Europe
            7.1.3. Asia Pacific
            7.1.4. Latin America
            7.1.5. Middle East & Africa
     7.2. Global Thyroid Gland Disorders Treatment Market Value Share Analysis, by Region
     7.3. Global Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Region

8. North America Thyroid Gland Disorders Treatment Market Analysis
     8.1. North America Thyroid Gland Disorders Treatment Market Key Findings
     8.2. North America Thyroid Gland Disorders Treatment Market Overview
     8.3. North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
            8.3.1. Hypothyroidism
                     8.3.1.1. Levothyroxine
                     8.3.1.2. Liothyronine
            8.3.2. Hyperthyroidism
                     8.3.2.1. Imidazole
                     8.3.2.2. Propacil
     8.4. North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
            8.4.1. Hypothyroidism
            8.4.2. Hyperthyroidism
     8.5. North America Thyroid Gland Disorders Treatment Market Forecast, by Country
            8.5.1. U.S.
            8.5.2. Canada
     8.6. North America Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
            8.6.1. Hypothyroidism
            8.6.2. Hyperthyroidism

9. Europe Thyroid Gland Disorders Treatment Market Analysis
     9.1. Europe Thyroid Gland Disorders Treatment Market Key Findings
     9.2. Europe Thyroid Gland Disorders Treatment Market Overview
     9.3. Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
            9.3.1. Hypothyroidism
                     9.3.1.1. Levothyroxine
                     9.3.1.2. Liothyronine
            9.3.2. Hyperthyroidism
                     9.3.2.1. Imidazole
                     9.3.2.2. Propacil
     9.4. Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
            9.4.1. Hypothyroidism
            9.4.2. Hyperthyroidism
     9.5. Europe Thyroid Gland Disorders Treatment Market Forecast, by Country
            9.5.1. Germany
            9.5.2. U.K.
            9.5.3. France
            9.5.4. Italy
            9.5.5. Spain
            9.5.6. Rest of Europe
     9.6. Europe Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
            9.6.1. Hypothyroidism
            9.6.2. Hyperthyroidism

10. Asia Pacific Thyroid Gland Disorders Treatment Market Analysis
     10.1. Asia Pacific Thyroid Gland Disorders Treatment Market Key Findings
     10.2. Asia Pacific Thyroid Gland Disorders Treatment Market Overview
     10.3. Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
            10.3.1. Hypothyroidism
                     10.3.1.1. Levothyroxine
                     10.3.1.2. Liothyronine
            10.3.2. Hyperthyroidism
                     10.3.2.1. Imidazole
                     10.3.2.2. Propacil
     10.4. Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
            10.4.1. Hypothyroidism
            10.4.2. Hyperthyroidism
     10.5. Asia Pacific Thyroid Gland Disorders Treatment Market Forecast, by Country
            10.5.1. China
            10.5.2. India
            10.5.3. Japan
            10.5.4. Australia & New Zealand
            10.5.5. Rest of Asia Pacific
     10.6. Asia Pacific Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
            10.6.1. Hypothyroidism
            10.6.2. Hyperthyroidism

11. Latin America Thyroid Gland Disorders Treatment Market Analysis
     11.1. Latin America Thyroid Gland Disorders Treatment Market Key Findings
     11.2. Latin America Thyroid Gland Disorders Treatment Market Overview
     11.3. Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
            11.3.1. Hypothyroidism
                     11.3.1.1. Levothyroxine
                     11.3.1.2. Liothyronine
            11.3.2. Hyperthyroidism
                     11.3.2.1. Imidazole
                     11.3.2.2. Propacil
     11.4. Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
            11.4.1. Hypothyroidism
            11.4.2. Hyperthyroidism
     11.5. Latin America Thyroid Gland Disorders Treatment Market Forecast, by Country
            11.5.1. Brazil
            11.5.2. Mexico
            11.5.3. Rest of Latin America
     11.6. Latin America Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
            11.6.1. Hypothyroidism
            11.6.2. Hyperthyroidism

12. Middle East & Africa Thyroid Gland Disorders Treatment Market Analysis
     12.1. Middle East & Africa Thyroid Gland Disorders Treatment Market Key Findings
     12.2. Middle East & Africa Thyroid Gland Disorders Treatment Market Overview
     12.3. Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
            12.3.1. Hypothyroidism
                     12.3.1.1. Levothyroxine
                     12.3.1.2. Liothyronine
            12.3.2. Hyperthyroidism
                     12.3.2.1. Imidazole
                     12.3.2.2. Propacil
     12.4. Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
            12.4.1. Hypothyroidism
            12.4.2. Hyperthyroidism
     12.5. Middle East & Africa Thyroid Gland Disorders Treatment Market Forecast, by Country
            12.5.1. GCC Countries
            12.5.2. South Africa
            12.5.3. Israel
            12.5.4. Rest of Middle East & Africa
     12.6. Middle East & Africa Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
            12.6.1. Hypothyroidism
            12.6.2. Hyperthyroidism

13. Competition Landscape
     13.1. Global Thyroid Gland Disorders Treatment Market Share Analysis, by Company (2016)
     13.2. Company Profiles
            13.2.1. Merck KGaA  
                     13.2.1.1. Overview (HQ, Employee Strength, Business Segments)
                     13.2.1.2. Financials
                     13.2.1.3. Recent Developments
                     13.2.1.4. Strategy
            13.2.2. Pfizer, Inc.  
                     13.2.2.1. Overview (HQ, Employee Strength, Business Segments)
                     13.2.2.2. Financials
                     13.2.2.3. Recent Developments
                     13.2.2.4. Strategy
            13.2.3. Takeda Pharmaceutical Company Limited
                     13.2.3.1. Overview (HQ, Employee Strength, Business Segments)
                     13.2.3.2. Financials
                     13.2.3.3. Recent Developments
                     13.2.3.4. Strategy
            13.2.4. ALLERGAN
                     13.2.4.1. Overview (HQ, Employee Strength, Business Segments)
                     13.2.4.2. Financials
                     13.2.4.3. Recent Developments
                     13.2.4.4. Strategy
            13.2.5. Sanofi S.A. 
                     13.2.5.1. Overview (HQ, Employee Strength, Business Segments)
                     13.2.5.2. Financials
                     13.2.5.3. Recent Developments
                     13.2.5.4. Strategy
            13.2.6. AbbVie Inc.  
                     13.2.6.1. Overview (HQ, Employee Strength, Business Segments)
                     13.2.6.2. Financials
                     13.2.6.3. Recent Developments
                     13.2.6.4. Strategy
            13.2.7. Lannett Company, Inc.
                     13.2.7.1. Overview (HQ, Employee Strength, Business Segments)
                     13.2.7.2. Financials
                     13.2.7.3. Recent Developments
                     13.2.7.4. Strategy
            13.2.8. Aspen
                     13.2.8.1. Overview (HQ, Employee Strength, Business Segments)
                     13.2.8.2. Financials
                     13.2.8.3. Recent Developments
                     13.2.8.4. Strategy
            13.2.9. Novartis AG
                     13.2.9.1. Overview (HQ, Employee Strength, Business Segments)
                     13.2.9.2. Financials
                     13.2.9.3. Recent Developments
                     13.2.9.4. Strategy
            13.2.10. Mylan N.V.
                     13.2.10.1. Overview (HQ, Employee Strength, Business Segments)
                     13.2.10.2. Financials
                     13.2.10.3. Recent Developments
                     13.2.10.4. Strategy

List of Tables

TABLE 1 Global Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Disorder, 2015–2025
TABLE 2 Global Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hypothyroidism Drug Class,
TABLE 3 Global Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hyperthyroidism Drug Class,
TABLE 4 Global Thyroid Gland Disorders Treatment Market Size (US$ Mn) Forecast, by Region, 2015–2025
TABLE 5 North America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Disorders, 2015–2025
TABLE 6 North America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hypothyroidism Drug Class, 2015–2025
TABLE 7 North America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hyperthyroidism Drug Class, 2015–2025
TABLE 8 North America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Country, 2015–2025
TABLE 9 Europe Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Disorder, 2015–2025
TABLE 10 Europe Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hypothyroidism Drug Class, 2015–2025
TABLE 11 Europe Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hyperthyroidism Drug Class, 2015–2025
TABLE 12 Europe Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 13 Asia Pacific Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Disorder, 2015–2025
TABLE 14 Asia Pacific Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hypothyroidism Drug Class, 2015–2025
TABLE 15 Asia Pacific Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hyperthyroidism Drug Class, 2015–2025
TABLE 16 Asia Pacific Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 17 Latin America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Disorder, 2015–2025
TABLE 18 Latin America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hypothyroidism Drug Class, 2015–2025
TABLE 19 Latin America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hyperthyroidism Drug Class, 2015–2025
TABLE 20 Latin America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 21 Middle East & Africa Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Disorders, 2015–2025
TABLE 22 Middle East & Africa Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hypothyroidism Drug Class, 2015–2025
TABLE 23 Middle East & Africa Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hyperthyroidism Drug Class, 2015–2025
TABLE 24 Middle East & Africa Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–202

List of Figures
 
FIG. 1 Global Thyroid Gland Disorders Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2025
FIG. 2 Global Thyroid Gland Disorders Market Value Share, by Disorders  (2016)
FIG. 3 Global Thyroid Gland Disorders Market Value Share, by Hypothyroidism Drug Class (2016)
FIG. 4 Global Thyroid Gland Disorders Market Value Share, by Region (2016)
FIG. 5 Global Thyroid Gland Disorders Market Value Share, by Hyperthyroidism Drug Class (2016)
FIG. 6 Global Thyroid Gland Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth, by Hypothyroidism, 2015–2025
FIG. 7 Global Thyroid Gland Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth, by Hyperthyroidism, 2015–2025
FIG. 8 Global Thyroid Gland Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth, by Levothyroxine, 2015–2025 
FIG. 9 Global Thyroid Gland Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth, by Liothyronine, 2015–2025
FIG. 10 Global Thyroid Gland Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth, by Imidazole, 2015–2025
FIG. 11 Global Thyroid Gland Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth, by Propacil, 2015–2025
FIG. 12 Global Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorder, 2016 and 2025
FIG. 13 Global Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hypothyroidism Drug Class, 2016 and 2025
FIG. 14 Global Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hyperthyroidism Drug Class, 2016 and 2025
FIG. 15 Global Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorder
FIG. 16 Global Thyroid Gland Disorders Treatment Market Value Share Analysis, by Region, 2016 and 2025
FIG. 17 Global Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Region
FIG. 18 North America Thyroid Gland Disorders Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth, 2015–2025
FIG. 19 North America Market Attractiveness Analysis, by Country
FIG. 20 North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders, 2016 and 2025
FIG. 21 North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hypothyroidism Drug Class, 2016 and 2025
FIG. 22 North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hyperthyroidism Drug Class, 2016 and 2025
FIG. 23 North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Country, 2016 and 2025
FIG. 24 North America Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorder
FIG. 25 Europe Thyroid Gland Disorders Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth, 2015–2025
FIG. 26 Europe Market Attractiveness Analysis, by Country
FIG. 27 Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorder, 2016 and 2025
FIG. 28 Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hypothyroidism Drug Class, 2016 and 2025
FIG. 29 Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hyperthyroidism Drug Class, 2016 and 2025
FIG. 30 Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
FIG. 31 Europe Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorder, 2015–2025
FIG. 32 Asia Pacific Thyroid Gland Disorders Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth, 2015–2025
FIG. 33 Asia Pacific Market Attractiveness Analysis, by Country/Sub-region
FIG. 34 Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorder, 2016 and 2025
FIG. 35 Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hypothyroidism Drug Class, 2016 and 2025
FIG. 36 Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hyperthyroidism Drug Class, 2016 and 2025
FIG. 37 Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
FIG. 38 Asia Pacific Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
FIG. 39 Latin America Thyroid Gland Disorders Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth, 2015–2025
FIG. 40 Latin America Market Attractiveness Analysis, by Country/Sub-region
FIG. 41 Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorder, 2016 and 2025
FIG. 42 Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hypothyroidism Drug Class, 2016 and 2025
FIG. 43 Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hyperthyroidism Drug Class, 2016 and 2025
FIG. 44 Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
FIG. 45 Latin America Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorder
FIG. 46 Middle East & Africa Thyroid Gland Disorders Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth, 2015–2025
FIG. 47 Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region
FIG. 48 Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorder, 2016 and 2025
FIG. 49 Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hypothyroidism Drug Class, 2016 and 2025
FIG. 50 Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hyperthyroidism Drug Class, 2016 and 2025
FIG. 51 Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
FIG. 52 Middle East & Africa Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorder
FIG. 53 Global Thyroid Gland Disorders Treatment Market Company Share Analysis (2016)
FIG. 54 Merck KGaA Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
FIG. 55 Merck KGaA Breakdown of Net Sales, by Region, 2016
FIG. 56 Breakdown of Net Sales, by Business Segment, 2016
FIG. 57 Merck KGaA R&D Expenses (US$ Bn) & Y-o-Y Growth (%), 2014–2016
FIG. 58 Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
FIG. 59 Pfizer, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2013–2016
FIG. 60 Pfizer, Inc. Breakdown of Net Sales, by Region, 2016
FIG. 61 Pfizer, Inc. Sales & Marketing Expenses (US$ Mn) and Y-o-Y Growth (%), 2013–2016
FIG. 62 Takeda Pharmaceutical Company Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
FIG. 63 Takeda Pharmaceutical Company Limited R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2013–2016
FIG. 64 Takeda Pharmaceutical Company Limited Breakdown of Net Sales, by Region
FIG. 65 Takeda Pharmaceutical Company Limited Sales & Marketing Expenses (US$ Mn) and Y-o-Y Growth (%), 2013–2016
FIG. 66 ALLERGAN Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
FIG. 67 ALLERGAN R&D Spending and Sales & Marketing Expenses – Company Level, 2015–2016
FIG. 68 ALLERGAN Breakdown of Net Sales, by Operating Segment, 2016
FIG. 69 Sanofi S.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
FIG. 70 Sanofi S.A. R&D Spending and Sales & Marketing Expenses – Company Level, 2014–2016
FIG. 71 Sanofi S.A. Breakdown of Net Sales, by Region, 2016
FIG. 72 Sanofi S.A. Breakdown of Net Sales, by Business Segment, 2016
FIG. 73 AbbVie Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
FIG. 74 AbbVie Inc. R&D Expenses and Sales & Marketing Expenses– Company Level, 2015–2016
FIG. 75 AbbVie Inc. Breakdown of Net Sales, by Region, 2016
FIG. 76 AbbVie Inc. Breakdown of Net Sales, by Major Brands, 2016
FIG. 77 Lannett Company, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
FIG. 78 Lannett Company, Inc. Breakdown of Net Sales, by Business Segments, 2016
FIG. 79 Lannett Company, Inc. Breakdown of Net Sales, by Customer Distribution Channel, 2016
FIG. 80 Aspen Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
FIG. 81 Aspen R&D Expenses and Sales & Marketing Expenses(%) – Company Level, 2015–2016
FIG. 82 Aspen Breakdown of Net Sales, By Region 2016
FIG. 83 Aspen Breakdown of Net Sales, (Overall Company Level), 2016
FIG. 84 Novartis AG Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
FIG. 85 Novartis AG R&D Expenses and Sales & Marketing Expenses(%) – Company Level, 2015–2016
FIG. 86 Novartis AG Breakdown of Net Sales, By Region 2016
FIG. 87 Novartis AG Breakdown of Net Sales, Business Segments, 2016
FIG. 88 Mylan N.V. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
FIG. 89 Mylan N.V. R&D Expenses and Sales & Marketing Expenses(%) – Company Level, 2015–2016
FIG. 90 Mylan N.V. Breakdown of Net Sales, By Region 2016
FIG. 91 Mylan N.V. Breakdown of Net Sales, Business Segments, 2016
Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved